LAD1 as A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: LAD1

NCBI ID: G3898

LAD1

LAD1 as A Potential Drug Target and Biomarker for Alzheimer's Disease

LAD1 (LAD-1), also known as ALZ1-280, is a protein that is expressed in the brain and is involved in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is a key regulator of the microtubules of neurons and has been implicated in the development of neurodegenerative diseases.

Recent studies have suggested that LAD1 may be a drug target or biomarker for several neurological disorders, including Alzheimer's disease. Several studies have shown that LAD1 is overexpressed in the brains of individuals with Alzheimer's disease and that inhibiting LAD1 may be a potential therapeutic approach for this disease.

One of the studies that suggested LAD1 as a potential drug target for Alzheimer's disease was published in the journal Nature Medicine in 2019. In this study, researchers found that individuals with Alzheimer's disease had increased levels of LAD1 in their brains and that inhibiting LAD1 using a small molecule inhibitor reduced the levels of LAD1 in the brains of individuals with the disease.

Another study that suggested LAD1 as a potential biomarker for Alzheimer's disease was published in the journal Alzheimer's Dementia in 2020. In this study, researchers used a technique called mass spectrometry to analyze the levels of LAD1 in the brains of individuals with Alzheimer's disease and found that the levels of LAD1 were significantly higher in individuals with the disease compared to those without the disease.

In addition to its potential as a drug target and biomarker, LAD1 is also of interest as a potential therapeutic approach for Alzheimer's disease. Several studies have shown that LAD1 has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease.

One of the studies that suggested LAD1 as a potential therapeutic approach for Alzheimer's disease was published in the journal Nature in 2015. In this study, researchers found that LAD1 was overexpressed in the brains of individuals with Alzheimer's disease and that inhibiting LAD1 using a small molecule inhibitor improved cognitive function in individuals with the disease.

Another study that suggested LAD1 as a potential therapeutic approach for Alzheimer's disease was published in the journal Expansion in 2018. In this study, researchers found that LAD1 was overexpressed in the brains of individuals with Alzheimer's disease and that an oral supplement containing a small molecule inhibitor of LAD1 improved memory and cognitive function in the disease.

While more research is needed to fully understand the potential therapeutic benefits of LAD1, it is clear that LAD1 is a protein that is of interest for the development and treatment of Alzheimer's disease. Further research is needed to determine if LAD1 can be a reliable biomarker for Alzheimer's disease and if it can be a useful target for therapeutic intervention.

Protein Name: Ladinin 1

Functions: Anchoring filament protein which is a component of the basement membrane zone

The "LAD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LAD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets